Virax Biolabs Launches Portfolio of Immune Profiling Solutions Evaluating Adaptive Immunity in Post-Viral Syndromes at ESCMID Global 2024 LONDON, April 25, 2024 /PRNewswire/ .
Virax Biolabs Group Limited (NASDAQ:VRAX – Get Free Report) saw a significant growth in short interest in the month of April. As of April 15th, there was short interest totalling 12,000 shares, a growth of 300.0% from the March 31st total of 3,000 shares. Based on an average daily trading volume, of 73,000 shares, the […]
Lantheus (NASDAQ:LNTH – Get Free Report) and Virax Biolabs Group (NASDAQ:VRAX – Get Free Report) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, profitability, dividends, risk, valuation, earnings and institutional ownership. Risk and Volatility Lantheus has a beta of […]
Virax Biolabs Group Limited (NASDAQ:VRAX – Get Free Report) was the target of a large decline in short interest in February. As of February 15th, there was short interest totalling 55,500 shares, a decline of 44.8% from the January 31st total of 100,500 shares. Approximately 4.2% of the shares of the stock are sold short. […]
Virax Biolabs Group Limited (NASDAQ:VRAX – Get Free Report) was the target of a large increase in short interest during the month of January. As of January 31st, there was short interest totalling 100,500 shares, an increase of 233.9% from the January 15th total of 30,100 shares. Based on an average daily volume of 124,700 […]